No Data
No Data
Bright Minds Biosciences Spotlights CNS Innovations at Key Conferences
Express News | Bright Minds Biosciences Announces Phase 2 Clinical Trial To Evaluate BMB-101 In Drug-Resistant Epilepsy Disorders With High Unmet Needs; Financial Runway Extends Into 2026, Webcast Scheduled For September 25th
Express News | Bright Minds Biosciences Initiates the Breakthrough Study: A Phase 2 Trial of Bmb-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Bright Minds Biosciences Financial Struggles Continue
No Data
No Data
Thatmyname :